ATE440602T1 - Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion - Google Patents
Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktionInfo
- Publication number
- ATE440602T1 ATE440602T1 AT00952302T AT00952302T ATE440602T1 AT E440602 T1 ATE440602 T1 AT E440602T1 AT 00952302 T AT00952302 T AT 00952302T AT 00952302 T AT00952302 T AT 00952302T AT E440602 T1 ATE440602 T1 AT E440602T1
- Authority
- AT
- Austria
- Prior art keywords
- stem cells
- progressor
- receptor agonists
- nicotine receptor
- cell induction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14623399P | 1999-07-28 | 1999-07-28 | |
US18830000P | 2000-03-10 | 2000-03-10 | |
PCT/US2000/020724 WO2001008683A1 (en) | 1999-07-28 | 2000-07-28 | Nicotine receptor agonists in stem cell and progenitor cell recruitment |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE440602T1 true ATE440602T1 (de) | 2009-09-15 |
Family
ID=26843696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00952302T ATE440602T1 (de) | 1999-07-28 | 2000-07-28 | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion |
Country Status (9)
Country | Link |
---|---|
US (1) | US6720340B1 (de) |
EP (1) | EP1207879B1 (de) |
JP (2) | JP2003505506A (de) |
AT (1) | ATE440602T1 (de) |
AU (1) | AU778386B2 (de) |
BR (1) | BR0012787A (de) |
CA (1) | CA2380052C (de) |
DE (1) | DE60042828D1 (de) |
WO (1) | WO2001008683A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838539B2 (en) * | 1999-07-28 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Nicotine receptor agonists in stem cell and progenitor cell recruitment |
US9364565B2 (en) | 2000-03-15 | 2016-06-14 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
EP1539152A4 (de) * | 2002-08-02 | 2006-10-18 | Nutraceutical Dev Corp | ENTWICKLUNG DER MUSKELMASSE IN EINEM SûUGETIER |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
AU2006331790A1 (en) * | 2005-12-19 | 2007-07-05 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses therof |
CA2649729A1 (en) * | 2006-04-17 | 2007-10-25 | Hepacore Ltd. | Methods for bone regeneration using endothelial progenitor cell preparations |
DK2055308T3 (en) * | 2006-10-30 | 2017-07-17 | Genomix Co Ltd | PHARMACEUTICALS FOR PROMOTING FUNCTIONAL REGENERATION OF DAMAGED TISSUE |
WO2008118370A2 (en) * | 2007-03-22 | 2008-10-02 | The Trustees Of The University Of Pennsylvania | Hyperbaric treatment in wound healing |
BRPI0911513A2 (pt) | 2008-04-30 | 2016-07-12 | Genomix Co Ltd | métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência |
JP5660889B2 (ja) | 2008-04-30 | 2015-01-28 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
BR112012009973A2 (pt) | 2009-10-28 | 2017-07-25 | Genomix Co Ltd | promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
CN114106139A (zh) | 2011-04-26 | 2022-03-01 | 斯特姆里姆有限公司 | 用于诱导组织再生的肽及其应用 |
PL2913058T3 (pl) | 2012-10-25 | 2018-04-30 | Genomix Co., Ltd. | Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1 |
SG11201503215XA (en) | 2012-10-25 | 2015-06-29 | Genomix Co Ltd | Novel method for treating spinal cord injury using hmgb1 fragment |
EP3052119B1 (de) | 2013-10-01 | 2018-08-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Verfahren zur erythropoiesemodulation mit arginin-vasopressin-rezeptor-1b-molekülen |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3613841B1 (de) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passives ersetzen von medien |
CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
MX2019008949A (es) | 2017-01-27 | 2019-10-07 | Stemrim Inc | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. |
US11702634B2 (en) | 2017-03-31 | 2023-07-18 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4321387A (en) | 1980-03-21 | 1982-03-23 | Philip Morris, Incorporated | Process for the preparation of optically active nicotine analogs |
US4442292A (en) | 1981-01-29 | 1984-04-10 | Philip Morris Incorporated | Optically active nicotine analogs and process for their preparation |
US4452984A (en) | 1981-01-29 | 1984-06-05 | Philip Morris, Inc. | Optically active nicotine analogs and process for their preparation |
US4332945A (en) | 1981-01-29 | 1982-06-01 | Philip Morris, Incorporated | Optically active nicotine analogs and process for their preparation |
US4590278A (en) | 1981-01-29 | 1986-05-20 | Philip Morris Incorporated | Nicotine analogs |
GB8330969D0 (en) | 1983-11-21 | 1983-12-29 | Wellcome Found | Promoting healing |
US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
US4943435A (en) | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US5318957A (en) | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
US5766948A (en) * | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
US5508030A (en) | 1993-08-05 | 1996-04-16 | Bierman; Howard R. | Creating new capillary blood pools for practicing bidirectional medicine |
WO2000023062A2 (en) * | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
US5830651A (en) * | 1995-06-01 | 1998-11-03 | Signal Pharmaceuticals, Inc. | Human oligodendroglial progenitor cell line |
AU2340397A (en) * | 1996-03-21 | 1997-10-10 | Mayo Foundation For Medical Education And Research | Use of nicotine to treat liver disease |
US5869037A (en) | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
US5866561A (en) | 1997-08-21 | 1999-02-02 | Scimed Life Systems, Inc. | Local delivery of estrogen for angiogenesis |
-
2000
- 2000-07-28 WO PCT/US2000/020724 patent/WO2001008683A1/en active IP Right Grant
- 2000-07-28 AU AU65026/00A patent/AU778386B2/en not_active Ceased
- 2000-07-28 EP EP00952302A patent/EP1207879B1/de not_active Expired - Lifetime
- 2000-07-28 DE DE60042828T patent/DE60042828D1/de not_active Expired - Lifetime
- 2000-07-28 JP JP2001513413A patent/JP2003505506A/ja active Pending
- 2000-07-28 US US09/627,643 patent/US6720340B1/en not_active Expired - Fee Related
- 2000-07-28 CA CA002380052A patent/CA2380052C/en not_active Expired - Fee Related
- 2000-07-28 BR BR0012787-6A patent/BR0012787A/pt not_active Withdrawn
- 2000-07-28 AT AT00952302T patent/ATE440602T1/de not_active IP Right Cessation
-
2008
- 2008-07-11 JP JP2008181465A patent/JP2008291040A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR0012787A (pt) | 2002-07-30 |
JP2003505506A (ja) | 2003-02-12 |
EP1207879A4 (de) | 2004-05-12 |
EP1207879A1 (de) | 2002-05-29 |
DE60042828D1 (de) | 2009-10-08 |
US6720340B1 (en) | 2004-04-13 |
AU778386B2 (en) | 2004-12-02 |
AU6502600A (en) | 2001-02-19 |
CA2380052A1 (en) | 2001-02-08 |
EP1207879B1 (de) | 2009-08-26 |
WO2001008683A1 (en) | 2001-02-08 |
CA2380052C (en) | 2007-10-23 |
JP2008291040A (ja) | 2008-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE440602T1 (de) | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion | |
DE60028971D1 (de) | Apo-2l rezeptor-agonist und cpt-11 synergie-effekt | |
DE69739856D1 (de) | Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen | |
ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
UA88463C2 (ru) | Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции | |
BR0013905A (pt) | Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag | |
ATE367169T1 (de) | Verwendung von exendins und deren agonisten zur behandlung von schwangerschaftsdiabetes | |
GEP20094845B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
WO2007087367A3 (en) | Methods and compositions for modulating the mobilization of stem cells | |
BR0016166A (pt) | Compostos de diidropirimidina heterocìclicos | |
ATE277628T1 (de) | Behandlung von hematopoietischen zellen mit cxcr4 agonisten | |
AP2001002129A0 (en) | 5HT1 receptor agonists and metoclopramide for the treatment of migrane. | |
SE0202598D0 (sv) | Alpha-7 Nicotinic receptor agonists and statins in combination | |
YU13301A (sh) | Muskarinski agonisti i antagonisti | |
MXPA05012319A (es) | Suministro de compuestos con celulas sanguineas rehidratadas. | |
NO2019032I1 (no) | Treosulfan | |
TW200501948A (en) | Composition for improving cognition and memory | |
WO2005079344A3 (en) | Nicotine receptor agonists in stem cell and progenitor cell recruitment | |
DE60014429D1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten | |
DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
BR9913846A (pt) | Antagonista receptor de quemocina e ciclosporina em terapia combinada | |
SE9804022D0 (sv) | Use of a parvovirus capsid particles in the inhibition of hematopoietic progenitor cells | |
DE60008589D1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten | |
NO20012169L (no) | Forbindelser med veksthormonfrigjörende egenskaper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |